

Chlamydia Infections - Pipeline Review, H2 2020

<https://marketpublishers.com/r/C81818E4A42EN.html>

Date: September 2020

Pages: 88

Price: US\$ 2,000.00 (Single User License)

ID: C81818E4A42EN

Abstracts

Chlamydia Infections - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2020, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles.

Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4

and 1 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Chlamydia Infections - Overview
- Chlamydia Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chlamydia Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chlamydia Infections - Companies Involved in Therapeutics Development
- Abera Bioscience AB
- Abivax SA
- BlueWillow Biologics Inc
- Erganeo
- Eurocine Vaccines AB
- Evoform Biosciences Inc
- Genetic Immunity Inc
- Lawrence Livermore National Laboratory
- Lead Discovery Center GmbH
- Merck & Co Inc
- Microbiotix Inc
- Prokarium Ltd
- QureTech Bio AB
- Traccine Pharmaceuticals
- Vault Pharma Inc
- Vaxine Pty Ltd
- Yaso Therapeutics Inc
- Chlamydia Infections - Drug Profiles
- (citric acid + lactic acid + potassium bitartrate) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

Ab-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ChlamyDerm - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia trachomatis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit CPAF for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 16S rRNA for Gonorrhoea and Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia Infections - Dormant Projects

Chlamydia Infections - Product Development Milestones

Featured News & Press Releases

May 12, 2020: Eurocine Vaccines receives notification of grant to prepare for the manufacture of the chlamydia vaccine candidate

May 07, 2020: Eurocine Vaccines presents end results from preclinical study with chlamydia vaccine

Jan 27, 2020: Eurocine Vaccines launches new preclinical study with chlamydia vaccine candidate

Aug 13, 2019: Progress made in developing first Chlamydia vaccine

Mar 13, 2019: Yaso Therapeutics awarded \$2 million SBIR grant from the National Institutes of Health to complete preclinical studies of a new female contraceptive that prevents disease transmission

Sep 26, 2018: BlueWillow Biologics awarded grant for chlamydia vaccine development

Apr 20, 2017: New weapon in fight against antibiotic resistance discovered

Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice

Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology

Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Chlamydia Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2020
Chlamydia Infections - Pipeline by Abivax SA, H2 2020
Chlamydia Infections - Pipeline by BlueWillow Biologics Inc, H2 2020
Chlamydia Infections - Pipeline by Erganeo, H2 2020
Chlamydia Infections - Pipeline by Eurocine Vaccines AB, H2 2020
Chlamydia Infections - Pipeline by Evofem Biosciences Inc, H2 2020
Chlamydia Infections - Pipeline by Genetic Immunity Inc, H2 2020
Chlamydia Infections - Pipeline by Lawrence Livermore National Laboratory, H2 2020
Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H2 2020
Chlamydia Infections - Pipeline by Merck & Co Inc, H2 2020
Chlamydia Infections - Pipeline by Microbiotix Inc, H2 2020
Chlamydia Infections - Pipeline by Prokarium Ltd, H2 2020
Chlamydia Infections - Pipeline by QureTech Bio AB, H2 2020
Chlamydia Infections - Pipeline by Traccine Pharmaceuticals, H2 2020
Chlamydia Infections - Pipeline by Vault Pharma Inc, H2 2020
Chlamydia Infections - Pipeline by Vaxine Pty Ltd, H2 2020
Chlamydia Infections - Pipeline by Yaso Therapeutics Inc, H2 2020
Chlamydia Infections - Dormant Projects, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chlamydia Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Abera Bioscience AB
Abivax SA
BlueWillow Biologics Inc
Erganeo
Eurocine Vaccines AB
Evoform Biosciences Inc
Genetic Immunity Inc
Lawrence Livermore National Laboratory
Lead Discovery Center GmbH
Merck & Co Inc
Microbiotix Inc
Prokarium Ltd
QureTech Bio AB
Traccine Pharmaceuticals
Vault Pharma Inc
Vaxine Pty Ltd
Yaso Therapeutics Inc

I would like to order

Product name: Chlamydia Infections - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/C81818E4A42EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C81818E4A42EN.html>